Clinical Trials Logo

Degenerative Osteoarthritis clinical trials

View clinical trials related to Degenerative Osteoarthritis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04255966 Active, not recruiting - Clinical trials for Arthroplasty Complications

Plasmafit® Revision Structan® Hip Endoprosthesis Cup

Start date: April 12, 2021
Phase:
Study type: Observational

The aim of this observational study is to collect clinical and radiological results of the new Plasmafit® Revision Structan® Hip Endoprosthesis Cup in a standard patient population and when used in routine clinical practice.

NCT ID: NCT03685110 Active, not recruiting - Clinical trials for Degenerative Osteoarthritis

CoreHip - Post Market Clinical Follow-Up Study

Start date: October 16, 2018
Phase:
Study type: Observational

The study is designed as a prospective, non-interventional multicentre cohort study. The product under Investigation will be used in Routine clinical practice and according to the authorized Instructions for Use (IfU). Aim of this observational study is to collect clinical and radiological results of the CoreHip® endoprosthesis system in a Standard Patient Population and when used in Routine clinical practice.

NCT ID: NCT03291470 Active, not recruiting - Clinical trials for Degenerative Osteoarthritis

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

Start date: December 9, 2021
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the efficacy and safety of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.

NCT ID: NCT03203330 Active, not recruiting - Clinical trials for Degenerative Osteoarthritis

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

Start date: October 30, 2018
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the safety and efficacy of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.